Dr. Lubomira Scherschun

Dr. Lubomira Scherschun completed her medical training at Wayne State University School of Medicine in 1998. 

Her interests are in cosmetic dermatology and skin cancer diagnosis and treatment. 

Dr. Scherschun completed her dermatology residency at Henry Ford Hospital in Detroit, Michigan.  She is a Board Certified Dermatologist and a fellow of the American Academy of Dermatology.

Many clinical trials, presentations, and publications have established Dr. Scherschun as an expert in her field. 

Living a healthy lifestyle is very important to Dr. Scherschun.  A self-proclaimed fitness enthusiast, she actively participates in strength training, Pilates, gyrotonics, ballet barre method, and spinning.

Dr. Scherschun is an avid PowerVibe user because “Whole Body Vibration fills a void in my exercise regimen because it’s so unique.  It’s a nice complement to all the other activities I take part in.  I can really feel and see the muscle toning.  I think WBV really helps with my balance and flexibility.  I never used to get sore before, but when using my PowerVibe, I get the good-sore feeling from working out.”

Dr. Scherschun has also followed the Peer reviewed literature that has been compiled for osteoporosis treatment.  “Another reason I enjoy using my PowerVibe is that I know it helps with my bone density."

“I continue to benefit from using my PowerVibe and encourage others to consider WBV as a new way to gain health benefits in less time.”

EXPERIENCE & EDUCATION

2007- Kaiser Permanente Southern California Medical Group:  Duties include staff dermatologist and teaching Harbor UCLA dermatology residents. 

2004-2007 Pharmaceutical Consultant:  worked as a consultant and/or  lecturer for Genentech, Amgen, Biogen IDEC  and Taro Pharmaceuticals.

2004-2007 Henry Ford Health System, Detroit, Michigan: Senior Tenured Attending Staff Physician-duties included teaching Henry Ford and Wayne State University dermatology residents and medical students, director of Psoriasis and Biologics Clinics,  director of Quality Assurance, clinical trials staff.  Awards included teacher of the year 2006.

2001-2004 Henry Ford Health System, Detroit, Michigan: Dermatology Residency: Clarence S. Livingood Fellowship in Dermatopharmacology and Photodermatology.

1998-1999 William Beaumont Hospital, Royal Oak, Michigan: Transitional year internship

1994-1998 Wayne State University School of Medicine  M.D., June 1998

1990-1994 Wayne State University B.S., Biology, summa cum laude

HONORS AND AWARDS

2004 Henry Ford Health System Dermatology Resident Award for best overall academic performance.

2000 Ligand Dermatology Research Scholar

2000 Photomedicine Society Award for best original research and presentation.

2000 Henry Ford Hospital Research Award  Narrow-band UVB Phototherapy Treatment for Vitiligo.

1998 Medical Alumni Senior Scholarship Award   Award to the senior who has performed at the highest scholastic level during the four-year period.

1998 Janet M. Glasgow Award  Award to the student who graduates first in her class

1998 Robert Rutzky Award  Award presented by the Department of Dermatology

1997 Medical Alumni Sophomore Scholarship Award

1996 Alpha Omega Alpha

1996 Year II Academic Achievement Award  Merit award for first class ranking

RESEARCH

1999 C.S. Livingood Clinical Dermatology Fellow

1997 Dermatology Basic Science Research Elective  Preceptor L. Boyd Savoy, M.D., Wayne State University.  Examined altered chemotactic phenomena in atopic dermatitis.

1991-1994 Oncology Basic Science Research Assistant  Preceptor James Onoda, PhD., Wayne State University.  Elucidated the role of radiation induced phenotypic changes in murine melanoma cells, murine carcinosarcoma cells, and human colon carcinoma cells.

PRESENTATIONS

-  Narrow-band UVB Phototherapy for Vitiligo lecture (November 1999) Michigan Dermatological Society.

-  Diltiazem Associated Photo-Distributed Hyperpigmentation lecture and paper  (March 2000) Photomedicine Society.

-  Narrow-band UVB Phototherapy for Non-psoriasis Indications lecture (March  2001) Photomedicine Society.

-  Phototherapy Desensitization of Photodermatoses  lecture (October 2001) Michigan Dermatological Society.

-  Anti-CD11a Therapy for Moderate to Severe Psoriasis lecture (October 2002) Michigan Dermatological Society

-  Grand Rounds lecture Wright State University (2005)

-  Adalimumab poster ( March 2005) American Academy of Dermatology

-  Grand Rounds lecture Henry Ford Hopsital (June 2006)

-  Symposium on Biologic Therapy  (July 2006) American Academy of Dermatology

-   Medical student lecture (February 2006) Wayne State University School of Medicine

-   Efalizumab Poster ( March 2006) American Academy of Dermatology

-   Medical student lecture ( February 2007) Wayne State University

-   Co-director  Efalizumab Advisory Board Panel  (July 2008) San Francisco

-  Alopecia Neoplastica poster (March 2009) American Academy of Dermatology.

PAST AND ACTIVE CLINICAL TRIALS

• A phase II, randomized parallel group, efficacy and safety study of BMS-234303 1%, 2% versus its vehicle QD or Minoxidil 5% in adult males with androgenetic alopecia.

• A double-blind, randomized vehicle-controlled study of DAP004 in patients with acne vulgaris.
• Clinical safety trial of “daily use” Penipro lotion in long-term use conditions.
• Long-term safety assessment of Helioblock SX cream in patients with polymorphous light eruption.
• A randomized, double blind, placebo-controlled study of clobetasol propionate foam, 0.05% in the treatment of mild to moderate plaque-type psoriasis of non-scalp regions
• A double-blind, randomized comparison of tazarotene gel and calcipotriol ointment for the treatment of body psoriasis.
• A double-blind, multicenter, randomized trial to determine the efficacy of FEMhrt in treating non-actinic facial skin aging in post-menopausal women.
• A double-blind, placebo-controlled, multicenter study to determine the effect of anti-CD11a on moderate to severe body plaque psoriasis.
• On site investigator for a double-blind, randomized, vehicle-controlled study to determine the efficacy of Helioblock SX (4 filter sunscreen) in preventing polymorphous light eruption.
• A double-blind, randomized, placebo-controlled, multicenter study to determine the effect of finasteride on hair loss in adult men with androgenic alopecia.
• A double-blind, placebo controlled, dose ranging clinical evaluation of GI198745 and finasteride in subjects with male pattern baldness.
• A prospective, multicenter, randomized, single-masked, controlled, clinical investigation of Dermagraft in patients with diabetic foot ulcers.
• An open label study to determine the safety and efficacy of topically applied tacrolimus ointment for the treatment of atopic dermatitis
• A prospective, multicenter, open-label, pilot study to evaluate the safety and efficacy of Apligraf for the treatment of venous leg ulcers that have failed to heal after receiving an autograft.
• A multicenter phase I/II open-label study of oral BCX-34 in the treatment of relapsed/refractory cutaneous T-cell lymphoma.
• Dynaflex vs. Jobst Ulcercare for the management of edema in venous insufficiency ulcerations
• A randomized, double-blind, placebo-controlled, parallel group, multicenter study to determine the efficacy of betamethasone valerate foam in the treatment of non-scalp psoriasis.
• A double-blind, randomized, placebo-controlled, multicenter, comparison/combination study with L-762943 and oral minocycline to determine their effects in young men with moderate to severe acne.
• A randomized, prospective, multi-site comparative 12 week study to evaluate wound healing, select performance characteristics and cost effectiveness of Mepilex technology dressing versus Duoderm CGF for the management of 60 patients with venous ulcers.
• A randomized, prospective multi-site study to evaluate the efficacy of a new transdermal S-caine anesthetic patch in children.
• Apligraf treatment for epidermolysis bullosa
• Narrow-band UVB Phototherapy for vitiligo
• A randomized, prospective, multi-center study to evaluate the efficacy of oral terbinafine for onychomycosis
• An open label trial to determine safety of tacrolimus 0.1% and 0.03% ointment.
• An open label study to determine efficacy of tacrolimus 0.1% ointment for pyodema gangrenosum.

PUBLICATIONS and POSTERS

Onoda JM., Kantak SS, Wilga GS, Zhang J, Sumner KJ, and Scherschun L.  Low dose radiation enhances cancer cell metastatic phenotype.  Proceedings of the 85^th Annual Meeting of the American Association for Cancer Research, p. 640, San Francisco, CA, 1994.

Kantak SS, Diglio CA, Sumner KJ, Scherschun L, Bossung DE, and Onoda JM.  Low dose radiation stimulates endothelial  cell receptor expression  resulting in increased tumor cell adhesion in vitro.  Proceedings of the 86^th Annual Meeting of the American Association for Cancer Research, Toronto, Ontario, 1995.

Grossberg E., Scherschun L, and Fivenson DP. Ulcerating Plantar Keratoderma in Systemic Association with Lupus Erythematosus.

Lupus. 2001;10(9): 650-2.

Scherschun L, Lee M, Lim HW. Diltiazem Associated Photo-distributed Reticulated Hyperpigmentation.

Archives Dermatol. 2001 Feb:137 (2): 179-82.

Grossberg E., Scherschun L, and Fivenson DP. Lupus Profundus: A Not Entirely Benign Disease.

Lupus.2001;107:514-6.

Byrd JA, Scherschun L, Chaffins M, Fivenson DP Eosinophilic dermatosis of myeloproliferative disease:characterization of a unique eruption in patients with hematologic disorders.

Arch Dermatol. 2001 Oct; 137 (10): 1378-80. Review. No abstract available. PMIK: 11594874 {PubMed – indexed for MEDLINE}

Scherschun L, Kim JJ, Lim HW.  Narrow-Band Ultraviolet B Phototherapy is a Safe and Effective Treatment of Vitiligo, accepted by J Am Acad Dermatol.

Reep M, Scherschun L, Choucair M, Shwayder T, and Fivenson D.: “The Use of a Bilayered Skin Construct in Inherited Epidermolysis Bullosa.”  Poster at 2000 Annual AAD Meeting.

Scherschun L, Kim JJ, Lim HW.  “Narrow-band UVB for the Treatment of Vitiligo.”  Poster at the 2000 Society for Investigative Dermatology Meeting.

Scherschun L, Cheung K, Fastenau J, Fivenson D.:  “Clinical Effectiveness of Graftskin for the Treatment of Venous Leg Ulcers.”  Poster at 13^th Annual Symposium on advanced Wound Care 2000.

Lim HW, Naylor M, Honigsmann H, Gilchrest BA, Cooper K, Morison W, DeLeo VA, Scherschun L. American Academy of Dermatology Consensus Conference on UVA Protection of Sunscreens: Summary and Recommendations.  Washington DC, Feb, 2000.  J Am Acad Dermatol. Mar:44(3):505-8.

Choucair M, Scherschun L, Fivenson DP.  Medical Simulations in Wound Care: Optimal Management of Chronic Venous Ulceration, InterMed Press.  May 2000.

Fivenson DP, Scherschun L, Reep M, Choucair MM.  “Graftskin Therapy for Epidermolysis Bullosa”  Poster at the 2001 Society for Investigative Dermatology Meeting.

Gathers R, Scherschun L, Fivenson DP, Lim HW.  “Narrow-band Ultraviolet B Phototherapy for Early Stage Mycosis Fungoides.”  Poster at the 2001 Society for Investigative Dermatology Meeting.

Scherschun L, Lim HW.  Book Review on Phototherapy Treatment Protocols for Psoriasis and Other Photoresponsive Dermatoses.  Accepted Archives Dermatol.

Scherschun L, Lim HW.  Photoprotection by Sunscreens.  Am J Clini Dermatol.  2001;2(3):131-4.

Cavorsi J, Kirsner RS, Moss S, Fivenson D, Scherschun L, Treatwell T, Shawkat L, Cheung K, Fastenau J. Apligraf Effectiveness and Cost in Closing Nonhealing Venous Leg Ulcers on the Clinical Setting. Submitted to Adv Skin & Wound Care.

Gathers RC, Scherschun L, Malick F, Fivenson DP, Lim HW.  Narrowband UVB phototherapy for early-stage mycosis fungoides.  J Am Acad Dermatol.2002 Aug 47 (2):191-7.

Fivenson D, Scherschun L.  Clinical and economic impact of Apilgraf for the treatment of nonhealing venous leg Ulcers.  Int J Dermatol. 2003 Dec; 42 (12): 960-5

Samson Yashar S, Gielczyk R, Scherschun L, Lim HW.  Narrow-band ultraviolet B treatment for vitiligo, pruritis, and inflammatory dermatoses. Photodermatol Photoimmunol Photomed.  2003 aug; 19 (4): 164-8

Fivenson DP, Scherschun L, Cohen LV.  Apligraf in the treatment of severe mitten deformity associated with

1. Plastic Reconst Surg. 2003 Aug; 112 (2)584-8

Fivenson DP, Scherschun L, Choucair M, Kukuruga D, Young J, Shwayder T.  Graftskin therapy in epidermolysis bullosa.  J Am Acad Dermatol. 2003 Jun; 48 (6):886-92.

Cohen DJ, Scherschun L.  Case Reaports:  Practical Experience with Efalizumab in Hand and Foot Psoriasis.  J Drugs Dermatol.  2007 Dec:6(12):1224-30.

Kohen, L, Scherschun L, Kerr H.  Alopecia Neoplastica.  Archives Dermatol.  (pedning press, accepted for publication 2009).